Innate Pharma : FULL-YEAR REPORT ON 'S LIQUIDITY CONTRACT WITH GILBERT DUPONT

 FULL-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH GILBERT DUPONT

Marseille, January 5, 2016

Under the liquidity contract entrusted by Innate Pharma to Gilbert Dupont, the following assets appeared on the liquidity account as at December 31, 2015:

-          22,128 shares of Innate Pharma, and
-          358,336.72 euros in cash

As a reminder, at June 30, 2015, the following assets appeared on the liquidity account:

-          26,811 shares of Innate Pharma, and
-          334,840.22 euros in cash

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

The Company has three clinical-stage programs, including two checkpoint inhibitors in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

Its    innovative     approach     has    translated     into    major    alliances     with    leaders    in    the biopharmaceutical industry such as Novo Nordisk A/S, Bristol-Myers Squibb and AstraZeneca.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 112 employees as at September 30, 2015.

Learn more about Innate Pharma at www.innate-pharma.com:
http://www.innate-pharma.com/.

Practical Information about Innate Pharma shares:

ISIN code Ticker code

FR0010331421 IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org:
http://www.amf-france.org/) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Innate Pharma	ATCG Press
Laure-Hélène Mercier Director, Investor Relations	Marie Puvieux (France) Mob: [phone]
Tel.: [phone]
[e-mail]: mailto:[e-mail]	[e-mail]: mailto:[e-mail]

 

               For additional information, please contact:

FULL-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT:
http://hugin.info/155662/R/1977758/724154.pdf

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INNATE PHARMA via Globenewswire

HUG#1977758